Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring—A nationwide cohort study
Open Access
- 1 October 2017
- journal article
- Published by Elsevier in Reproductive Toxicology
- Vol. 73, 196-200
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before PregnancyObstetrics & Gynecology, 2017
- The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal ExposureInflammatory Bowel Diseases, 2017
- Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel DiseaseGastroenterology, 2017
- The toxicity of methotrexate in male fertility and paternal teratogenicityExpert Opinion on Drug Metabolism & Toxicology, 2016
- The incidence of ulcerative colitis (1995–2011) and Crohn's disease (1995–2012) — Based on nationwide Danish registry dataJournal of Crohn's and Colitis, 2014
- Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Association of Family History of Autoimmune Diseases and Autism Spectrum DisordersPediatrics, 2009
- Therapeutic Drug Use in Women With Crohn's Disease and Birth Outcomes: A Danish Nationwide Cohort StudyAmerican Journal of Gastroenterology, 2007
- Teratogen update: Azathioprine and 6‐mercaptopurineTeratology, 2002
- Prenatal Exposures and Childhood CancerPediatric and Developmental Pathology, 1999